Ascendis Pharma A/S
Every calculator, already run for ASND
Open the full toolkit →You have the numbers on ASND. Get the argument.
A written report on which of these readings actually decide the outcome for Ascendis Pharma A/S, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
20 analysts covering ASNDAnalyst Price Target Disagreement for Ascendis Pharma A/S
Wall Street's bull case implies +58% from the current price; the bear case implies +18%. A 40% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ASND
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
ASND — frequently asked
Is ASND a buy right now?
Wall Street's consensus rating on Ascendis Pharma A/S is Strong Buy across 20 analysts, with a mean price target of $310.30 (+38% vs. the current $225.60). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ASND overvalued?
ASND trades at 17.7x trailing earnings, against a DCF fair value of $4 per share. The current price implies 50% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Ascendis Pharma A/S?
Analysts covering Ascendis Pharma A/S (ASND) range from a bear-case target of $266.64 to a bull-case high of $355.77, with a mean consensus target of $310.30 across 20 analysts. The spread of $89.13 (40% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Ascendis Pharma A/S against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Ascendis Pharma A/S
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ASND research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Ascendis Pharma A/S, in minutes. 3 free reports included with every account — no credit card required.